Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalation and Dose Expansion, Phase I Study of BR105 Injection to Evaluate the Safety, Tolerability and Antitumor Activity in Patients With Advanced Malignant Tumors

NCT05351697 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05351697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalation and Dose Expansion, Phase I Study of BR105 Injection to Evaluate the Safety, Tolerability and Antitumor Activity in Patients With Advanced Malignant Tumors
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
April 19, 2022
Completion date
October 30, 2025
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies